Objective: To determine the safety of intrathecal autologous adipose-derived mesenchymal stromal cell treatment for amyotrophic lateral sclerosis (ALS).
Scale (ALSFRS-R) questionnaire, neurologic examination, physical examination, blood sample (weeks 1 and 3), CSF samples (weeks 1 and 4), and gadolinium-enhanced MRI of the brain and spinal cord (week 3). In participants receiving the 2 monthly treatments, the weekly follow-up visits were repeated for a total of 8 weeks. Subsequently, participants were followed up every 3 months until 2 years, death, or loss to follow-up.
RESULTS After providing Institutional Review
Board-approved informed consent, 27 patients with clinically definite ALS by El Escorial criteria were enrolled and treated in this dose-escalation safety clinical trial (table) . The median age was 57 years (range 36-75 years), and the ratio of male to female patients was 15:12. The median ALSFRS-R at enrollment was 39 (range 27-47). Twenty of 27 patients had spinal-onset ALS, and 7 of 27 had bulbar onset.
Adverse events that were considered to be possibly, probably, or definitely related to intrathecal MSCs were observed in a dose-dependent fashion. Participant 2-4 had 24 hours of headache after treatment (not position dependent). Eight of the 10 participants receiving 1 3 10 8 MSC dose developed low back and leg pain that began within a week of treatment, peaked in the first 3 weeks, and then resolved or became very mild (1 of 10 on visual analog scale). The pain was exacerbated by the straight leg raise test and exhibited variable intensity (2-8 of 10 on visual analog scale) and duration (range 42-77 days) among the participants. Analgesics were used during pain in 5 of 8 patients, including nonsteroidal anti-inflammatory drugs (5), gabapentin (3), and opioids (2). In participant 5-2, the pain led to postponement of the second treatment by 2 months until pain had resolved. The pain recurred on the second injection, lasting 2 months. Although the study was not designed for efficacy, ALSFRS-R questionnaires were performed throughout the study and showed progression in all patients that did not appear, and was not reported by any patients, to be more rapid than before therapy ( figure 1) . Notably, 17 of 29 participants reported specific mild temporary subjective clinical improvements (typically lasting ,2 months), which were reported (with overlap) as improved bulbar function (n 5 8), increased limb strength (n 5 5), decreased fasciculations (n 5 4), decreased stiffness (n 5 4), and improved energy (n 5 4). Because this trial was not blinded or placebo controlled, these effects cannot be interpreted as a positive treatment response to MSC treatment.
Lumbar punctures were performed at weeks 1 and 4 after intrathecal MSC treatment. Dose-dependent alterations of CSF parameters were observed. In aggregate within the different doses, CSF protein increased from baseline (mean 5 56.4 mg/dL, SEM 5 4.0 mg/dL) to week 1 (mean 5 93.4 mg/dL, SEM 5 18.7 mg/dL) and week 4 (mean 5 189.2 mg/dL, SEM 5 111.0 mg/dL) after intrathecal MSCs administration. There was also an increase in CSF nucleated cells (monocytes) from baseline (1.2 cells/mL, SEM 0.3 cell/mL) to week 1 (mean 5 9.2 cells/mL, SEM 5 2.5 cells/mL) that began to decrease by week 4 (mean 5 4.7 cells/mL, SEM 5 1.5 cells/mL). Glucose decreased slightly between baseline and weeks 1 and 4. No abnormal CSF oligoclonal bands or neoplastic cytology was observed in any sample. Grouped data by dose level are reported in figure 2 , and individual data are included in the table.
MRI of the brain and spinal cord was completed, when tolerated, at week 3 after intrathecal MSCs. Abnormalities were observed in the lumbosacral nerve roots in 1 of 5 patients receiving 1 3 10 7 , 9 of 12 receiving 5 3 10 7 , and 9 of 10 in the 1 3 10 8 dose group. In these cases, the primary finding was lumbosacral nerve root thickening with clumping and gadolinium enhancement, reminiscent of arachnoiditis, which increased in severity with increasing dose (figure 2). In participant 2-1, the first participant whom we observed to have clear lumbosacral nerve root abnormalities, repeat MRI was performed at week 22 after treatment and was unchanged. CSF in participant 2-1 was also repeated at week 22 and normalized.
Four patients who died in this study underwent autopsy at a range of 31 days to 54 weeks after MSC treatment (3 of whom had abnormalities on MRI lumbosacral spine). Gross pathology did not reveal any signs of tumor formation or frank arachnoiditis in any of these cases. DISCUSSION Overall, intrathecal administration of MSCs in patients with ALS was safe. We observed dose-dependent changes in MRI of lumbosacral spine, CSF parameters, and temporary lumbosacral-radicular pain, all of which were tolerable. We postulate that this temporary pain relates to nerve root irritation and inflammation from MSC administration. Notably, in the 4 patients who underwent autopsies, there were no signs of tumor formation, which has been a concern with cell-based therapies. Studies are ongoing to investigate autopsy material for microscopic signs of MSC engraftment or neuroinflammation.
This phase I clinical trial of intrathecal adiposederived MSC therapy in patients with definite ALS by El Escorial criteria corroborates other studies that have demonstrated safety of intrathecal bone marrow-derived MSCs in ALS. [4] [5] [6] [7] Although still debated, MSCs from adipose and bone marrow have similar properties, and adipose harvesting is a simpler, well-tolerated procedure. These safety data support the exploration of adipose-derived MSCs in other neurologic conditions.
Our data do not directly address the efficacy of intrathecal MSC therapy in ALS; however, we feel that the excellent safety profile justifies further investigation of this product. Notably, while we report anecdotal mild temporary subjective clinical improvements in our treatment regimen, we did not see miraculous improvements in or cessation of progression in any patients. These data may temper the sometimes irrationally exuberant enthusiasm for this therapy modality. Future studies are required to determine the efficacy and whether earlier intervention or additional MSC treatments are required to produce meaningful results. In this small phase I study, 1 3 10 8 MSCs were tolerated, yet this dose also caused more painful adverse effects. Our planned multidose phase II study initiates treatment at 1 3 10 8 MSCs but incorporates an algorithm that allows lower doses when there is protracted pain.
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